Headquartered in Novo Hamburgo, Rio Grande do Sul, the Brazilian Association of Companies of Components for Leather, Footwear ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...

(Reuters) -Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to develop drugs for cardiometabolic diseases, including obesity ...

Novo Nordisk has added another dimension to its artificial intelligence ambitions by signing up as a customer of Denmark’s first so-called “supercomputer.” The supercomputer, named Gefion ...

Novo Nordisk’s shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe’s largest by market capitalization. Steven Goldstein is based in London ...

Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep Apple Therapeutics to access small molecules against a non-incretin GPCR ...

Novo Nordisk reported that it is advancing amycretin to a phase 3 study. The company is making the move after receiving feedback on earlier-stage testing. In the final phase, both subcutaneous and ...

Novo Nordisk (NVO) announced Thursday it will start a late-stage clinical program next year to evaluate its new obesity therapy amycretin in subcutaneous and oral formulations. Amycretin, a long ...

French banking group BPCE has emerged as the leading bidder to acquire Portuguese lender Novo Banco SA from Lone Star Funds, people with knowledge of the matter said. BPCE has pulled ahead of its ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

Shares in the Danish drugmaker climbed as much as 2.3 per cent on Friday (Jun 13) after Novo said it plans to advance its experimental weight management treatment amycretin into late-stage development ...